Exclusive Interview: Julian Bahr, Postdoctoral Fellow at AstraZeneca and Speaker at 3D Cell Culture Conference
SMi Reports: Speaker interview from AstraZeneca released ahead of SMi’s 5th Annual 3D Cell Culture taking place on 10 – 11 February 2021 as a virtual conference with online access only.
London, United Kingdom, December 18, 2020 --(PR.com)-- SMi Group had the opportunity to speak with our key speaker Julian Bahr, Postdoctoral Fellow at AstraZeneca for the conference, to discuss some of the challenges they face in the industry and their strategies for overcoming them.
Julian Bahr has been a Postdoctoral Fellow at AstraZeneca since 2018, where he is developing new 3D models for immunotherapy target discovery. His scientific training began at the National Institutes of Health under Dr. Susan Bates studying the mechanisms of HDAC and MAPK pathway inhibitors on KRAS mutant cancers. He went on to research macrophage-mediated basement membrane remodeling with Dr. Stephen Weiss for his Ph. D. work at the University of Michigan. Julian is passionate about elevating Ph.D. and Postdoctoral science and has continuously held leadership positions in the research organizations he has been a part of.
Julian Bahr in depth speaker interview can be downloaded on the conference website www.3D-cellculture.com/PR3 in the "download centre,', and below is a snippet of the exclusive interview.
What is the greatest challenge for you to personally overcome within the 3D Cell Culture field currently?
"Our greatest challenge has been to push high throughput 3D imaging to be more complex and therefore, more relevant to patient biology. We hope that recapitulating these phenotypes consistently and easily will open up a new world of drug screening applications."
How would you like to see the 3D Cell Culture market develop in the future and where do you think the biggest growth area will be in the next few years?
"I would like to see the market continue to make it easier for non-specialists to use complex 3D systems for drug discovery work. I think widespread adoption of these systems to reduce the number of expensive animal studies but improve on the relevance of 2D models will grow in the next few years."
Registration is £499 for active Pharmaceutical Professionals and vendors/commercial firms is £999, visit www.3D-cellculture.com/PR3
For sponsorship enquiries contact Alia Malick on +44 (0)20 7827 6164 or amalick@smi-online.co.uk
For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6162 or ssapal@smi-online.co.uk
SMi’s 5th Annual 3D Cell Culture Conference
Conference: 10th - 11th February 2021
Virtual Conference: Online Access Only
http://www.3D-cellculture.com/PR3
#SMi3DCellCulture
About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Julian Bahr has been a Postdoctoral Fellow at AstraZeneca since 2018, where he is developing new 3D models for immunotherapy target discovery. His scientific training began at the National Institutes of Health under Dr. Susan Bates studying the mechanisms of HDAC and MAPK pathway inhibitors on KRAS mutant cancers. He went on to research macrophage-mediated basement membrane remodeling with Dr. Stephen Weiss for his Ph. D. work at the University of Michigan. Julian is passionate about elevating Ph.D. and Postdoctoral science and has continuously held leadership positions in the research organizations he has been a part of.
Julian Bahr in depth speaker interview can be downloaded on the conference website www.3D-cellculture.com/PR3 in the "download centre,', and below is a snippet of the exclusive interview.
What is the greatest challenge for you to personally overcome within the 3D Cell Culture field currently?
"Our greatest challenge has been to push high throughput 3D imaging to be more complex and therefore, more relevant to patient biology. We hope that recapitulating these phenotypes consistently and easily will open up a new world of drug screening applications."
How would you like to see the 3D Cell Culture market develop in the future and where do you think the biggest growth area will be in the next few years?
"I would like to see the market continue to make it easier for non-specialists to use complex 3D systems for drug discovery work. I think widespread adoption of these systems to reduce the number of expensive animal studies but improve on the relevance of 2D models will grow in the next few years."
Registration is £499 for active Pharmaceutical Professionals and vendors/commercial firms is £999, visit www.3D-cellculture.com/PR3
For sponsorship enquiries contact Alia Malick on +44 (0)20 7827 6164 or amalick@smi-online.co.uk
For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6162 or ssapal@smi-online.co.uk
SMi’s 5th Annual 3D Cell Culture Conference
Conference: 10th - 11th February 2021
Virtual Conference: Online Access Only
http://www.3D-cellculture.com/PR3
#SMi3DCellCulture
About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Contact
SMi Group
Simi Sapal
+44 (0) 20 7827 6162
http://www.3D-cellculture.com/PR3
Simi Sapal
+44 (0) 20 7827 6162
http://www.3D-cellculture.com/PR3
Contact
Categories